Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. The ...

Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company. With a market cap of ...

JPMorgan analysts said in a note Wednesday that while the recent equity market rebound has lost momentum, any short-term pullback in large-cap stocks should be viewed as a “buy the dip” opportunity.

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb has teamed up with BioNTech to co-develop a bispecific antibody, BNT327, targeting multiple solid tumors ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...